Action Roche - 1RO

Roche Holding AG (1RO) Action

Votre Hub pour des idées et discussions en direct en temps réel

Premium

Dernier

( - )

Prix Achat

Prix Vente

Volume échangé

0,00 Fourchette du Jour 0,00

0,00 Plage de 52 semaines 0,00

Cap du marché

Clôture Veille

Ouverture

Dernière Transaction

Dernière heure de transaction

Volume financier

VWAP

Volume moyen (3 m)

1 003 923 €

Actions en circulation

795 617 637

Rendement du Dividende (LTM)

9,8 (3,11%)

Ratio Cours sur Bénéfices

20,5

Bénéfice par action (BPA)

16,04

Chiffre d'affairess (LTM)

63,36B

Bénéfice net (LTM)

12,88B

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases... Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions. Roche Holding AG has a collaboration agreement with Excalipoint Therapeutics to evaluate EXP011 in DLL3-expressing solid tumors. The company was founded in 1896 and is based in Basel, Switzerland. Show more

Secteur

Industrie

Site Web

www.roche.com

Siège social

Basel, Switzerland

Fondé

1896

Roche Holding AG est coté dans le secteur de la Italian Stock Exchange avec le ticker 1RO. Le dernier cours de clôture d'Roche était de -. Au cours de la dernière année, les actions de Roche ont été négociées dans une fourchette de prix de 0,00 € à 0,00 €.

Roche compte actuellement 795 617 637 actions en circulation. Roche a un ratio cours/bénéfice (ratio PE) de 20.50.

[Ad hoc announcement pursuant to Art. 53 LR] Roche’s divarasib shows superiority in head-to-head phase III trial against approved KRAS G12C inhibitors in non-small cell lung cancer

[Ad hoc announcement pursuant to Art. 53 LR] Roche’s divarasib shows superiority in head-to-head phase III trial against approved KRAS G12C...

FDA grants Priority Review to Roche’s Enspryng, the first and only at-home subcutaneous treatment option for thyroid eye disease (TED)

FDA grants Priority Review to Roche’s Enspryng, the first and only at-home subcutaneous treatment option for thyroid eye disease (TED) The filing...

Roche announces the launch of AXELIOS 1, a transformative next-generation sequencing platform

Roche announces the launch of AXELIOS 1, a transformative next-generation sequencing platform AXELIOS 1 delivers a unique combination of accuracy...

FDA accepts supplemental Biologics License Application for Roche’s Lunsumio and Polivy combination for people with relapsed or refractory large B-cell lymphoma

FDA accepts supplemental Biologics License Application for Roche’s Lunsumio and Polivy combination for people with relapsed or refractory large...

Roche receives FDA approval for the first companion diagnostic to assess PTEN protein in people living with prostate cancer

Roche receives FDA approval for the first companion diagnostic to assess PTEN protein in people living with prostate cancer The new VENTANA PTEN...

FDA grants Priority Review for Roche’s Tecentriq for a certain type of stage III colon cancer

FDA grants Priority Review for Roche’s Tecentriq for a certain type of stage III colon cancer Filing acceptance is based on the phase III Alliance...

Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurology

Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg...

FDA accepts New Drug Application for Roche’s giredestrant in ER-positive early-stage breast cancer, the first and only oral SERD with positive phase III results in the curative setting

FDA accepts New Drug Application for Roche’s giredestrant in ER-positive early-stage breast cancer, the first and only oral SERD with positive...

Roche to present new data advancing its obesity portfolio at the American Diabetes Association’s 2026 Scientific Sessions

Roche to present new data advancing its obesity portfolio at the American Diabetes Association’s 2026 Scientific Sessions Late-breaking Phase II...

Roche launches the Liver Disease Panel, the first suite of certified algorithms to support Chronic Liver Disease management

Roche launches the Liver Disease Panel, the first suite of certified algorithms to support Chronic Liver Disease management Roche introduces the...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

1RO - Frequently Asked Questions (FAQ)

What is the current Roche Holding AG share price?

The current share price of Roche Holding AG is 0,00 €

How many Roche Holding AG shares are in issue?

Roche Holding AG has 795 617 637 shares in issue

What is the 1 year trading range for Roche Holding AG share price?

Roche Holding AG has traded in the range of 0,00 € to 0,00 € during the past year

What is the PE ratio of Roche Holding AG?

The price to earnings ratio of Roche Holding AG is 20,5

What is the cash to sales ratio of Roche Holding AG?

The cash to sales ratio of Roche Holding AG is 4,14

What is the registered address of Roche Holding AG?

The registered address for Roche Holding AG is Grenzacherstrasse 124, Basel, Basel-Stadt, 4070

What is the Roche Holding AG website address?

The website address for Roche Holding AG is www.roche.com

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Roche Holding AG (1RO)

Roche Holding AG (1RO) Action

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

À propos de Roche Holding AG

1RO Dernières nouvelles

[Ad hoc announcement pursuant to Art. 53 LR] Roche’s divarasib shows superiority in head-to-head phase III trial against approved KRAS G12C inhibitors in non-small cell lung cancer

FDA grants Priority Review to Roche’s Enspryng, the first and only at-home subcutaneous treatment option for thyroid eye disease (TED)

Roche announces the launch of AXELIOS 1, a transformative next-generation sequencing platform

FDA accepts supplemental Biologics License Application for Roche’s Lunsumio and Polivy combination for people with relapsed or refractory large B-cell lymphoma

Roche receives FDA approval for the first companion diagnostic to assess PTEN protein in people living with prostate cancer

FDA grants Priority Review for Roche’s Tecentriq for a certain type of stage III colon cancer

Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurology

FDA accepts New Drug Application for Roche’s giredestrant in ER-positive early-stage breast cancer, the first and only oral SERD with positive phase III results in the curative setting

Roche to present new data advancing its obesity portfolio at the American Diabetes Association’s 2026 Scientific Sessions

Roche launches the Liver Disease Panel, the first suite of certified algorithms to support Chronic Liver Disease management

[Ad hoc announcement pursuant to Art. 53 LR] Roche’s divarasib shows superiority in head-to-head phase III trial against approved KRAS G12C inhibitors in non-small cell lung cancer

FDA grants Priority Review to Roche’s Enspryng, the first and only at-home subcutaneous treatment option for thyroid eye disease (TED)

Roche announces the launch of AXELIOS 1, a transformative next-generation sequencing platform

FDA accepts supplemental Biologics License Application for Roche’s Lunsumio and Polivy combination for people with relapsed or refractory large B-cell lymphoma

Roche receives FDA approval for the first companion diagnostic to assess PTEN protein in people living with prostate cancer

FDA grants Priority Review for Roche’s Tecentriq for a certain type of stage III colon cancer

Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurology

FDA accepts New Drug Application for Roche’s giredestrant in ER-positive early-stage breast cancer, the first and only oral SERD with positive phase III results in the curative setting

Roche to present new data advancing its obesity portfolio at the American Diabetes Association’s 2026 Scientific Sessions

Roche launches the Liver Disease Panel, the first suite of certified algorithms to support Chronic Liver Disease management

Roche to present new data at ASCO 2026, reinforcing giredestrant's potential to transform the treatment paradigm in early breast cancer

Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)

1RO - Frequently Asked Questions (FAQ)

1RO Transactions

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Sign up for FREE and get:

Supprimer les publicités

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE